22 Sep 2016 07:00
22 September 2016
Venn Life Sciences Holdings Plc
("Venn" or the "Company" or the "Group")
Appointment of Non-Executive Director
Venn Life Sciences (AIM: VENN), a growing Contract Research Organisation (CRO) providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces the appointment of Mary Sheahan as a Non-Executive Director ('NED') to the Board with immediate effect.
Mary Blake Sheahan, aged 44, is a dedicated senior leader with over 20 years' experience, at Executive Committee level of a multinational publicly listed biopharmaceutical company. Mary's most recent role was as Senior Vice President of Global Integration and Country Manager for Ireland with Perrigo Company plc, a NYSE-listed, $13 billion market cap leading global healthcare supplier. In this role, she was responsible for the successful integration of a $4.5bn acquisition of a leading European OTC Healthcare Company with operations in 35 countries.
Prior to this, Mary was Executive Vice President and Group Head of HR, IT, Facilities & Portfolio Assessment Management at Elan Corporation plc prior to its merger with Perrigo in 2013. Mary is a qualified chartered accountant having trained with KPMG.
Tony Richardson, Chief Executive Officer of Venn said: "Mary will be a great addition to the Board in a time of great progress and change at Venn. She has a proven track record of setting direction, strategic decision-making and delivering results in complex and challenging situations, across a range of disciplines including finance, strategy and commercial functions. She will add considerable value to our team.
Mary has confirmed that there are no other items requiring disclosure in accordance with Schedule 2(g)(iii) to (viii) of the AIM rules and the ESM Rules.
Current directorships or partnerships | Directorships or partnerships in the last five years |
Madiba Consulting Limited Elan Science Three Limited |
Prothena Corporation, plc Perrigo Holdings Limited Perrigo Corporation Limited Janssen Alzheimer Immunotherapy Unlimited Perrigo Finance plc |
Mary does not hold any interests in ordinary shares of Venn.
Enquiries:
Venn Life Sciences Holdings Plc | |||
Allan Wood, Chairman | Tel: +447185325898 | ||
Tony Richardson, Chief Executive Officer | Tel: +353 154 99 341 | ||
Davy (Nominated Adviser, ESM Adviser and Joint Broker) | |||
Fergal Meegan / Matthew de Vere White (Corporate Finance) | Tel: +353 1 679 6363 | ||
Orla Bolger (Corporate Broking) | |||
Hybridan LLP (Co-Broker) | |||
Claire Louise Noyce | Tel: +44(0) 20 3764 2341 | ||
Walbrook PR Ltd | Tel: +44(0)20 7933 8787 or venn@walbrookpr.com | ||
Paul McManus | Mob: +44(0) 7980 541 893 | ||
Lianne Cawthorne | Mob: +44(0) 7584 391 303 | ||
About Venn Life Sciences:
Venn Life Sciences (AIM: VENN), a growing Contract Research Organisation (CRO) providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects. Venn also has an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science.